Dr. Hui Wang: A Simple and Rapid Multi-Parameter Flow Cytometry Approach for the Diagnosis and Screening of Malignant Tumors and Related Diseases

Dr. Hui Wang: A Simple and Rapid Multi-Parameter Flow Cytometry Approach for the Diagnosis and Screening of Malignant Tumors and Related Diseases

From June 8 to 12, 2023, the 28th European Hematology Association (EHA) Congress will be held in Frankfurt, Germany, bringing together experts and scholars from around the world to present exciting advances in research. In the field of hematology testing, multi-parameter flow cytometry (MFC) is an important clinical diagnostic method, and the development of fast, simple, and efficient protocols is essential for this technology. A real-world study (P588) conducted by Dr.  Hui Wang's team from Hebei Yanda Ludaopei Hospital and Beijing Ludaopei Hospital has been selected for presentation at EHA. The study aims to introduce the research achievements of Ludaopei Hospital over the years: a rapid, simple, and efficient MFC test for screening and diagnosing malignant tumors and related diseases. To gain a deeper understanding of this research, "Oncology Insight" invited Professor Wang Hui to provide a detailed analysis, which is summarized below.
Dr.  Huilai Zhang’s Team: Key Research in the Field of Hodgkin Lymphoma

Dr.  Huilai Zhang’s Team: Key Research in the Field of Hodgkin Lymphoma

The 28th European Hematology Conference/Annual Meeting (28th EHA Congress) was successfully held in Frankfurt, Germany from June 8-11, 2023. The conference was organized by the European Hematology Association (EHA). As one of the largest international conferences in the field of hematology worldwide, the EHA annual meeting gathered top hematology experts from around the globe, covering all aspects of hematology research. The conference featured oral presentations, poster presentations, and several other sessions. This edition of Oncology Frontier focuses on key clinical studies on Hodgkin lymphoma presented in the oral report session, providing a quick overview of the latest research advancements in this area.
Dr. Niels Van de Donk Interprets the Latest Research Progress on CAR-T Treatment for RRMM

Dr. Niels Van de Donk Interprets the Latest Research Progress on CAR-T Treatment for RRMM

From June 8th to 11th, 2023, the 28th European Hematology Association (EHA) was held in Frankfurt, Germany, both online and offline. The conference was hosted by the European Hematology Association. As the largest international conference in the European hematology field, it attracts over 10,000 professionals from more than 100 countries each year to share and discuss innovative concepts and the latest scientific and clinical research results in hematology. At the EHA conference site, Oncology Frontier specially invited Professor Niels Van de Donk from Amsterdam University Medical Center (AMC-UvA) to interpret the latest research and future direction of CAR-T in the treatment of relapsed/refractory multiple myeloma (RRMM)
Dr. Qian Jiang: Reduced Dosage without Reducing Efficacy, Better Quality of Life for Patients

Dr. Qian Jiang: Reduced Dosage without Reducing Efficacy, Better Quality of Life for Patients

From June 8th-11th, 2023, the 28th European Hematology Association (EHA) conference was held in Frankfurt, Germany. At the EHA meeting, Professor Jiang Qian's team from Peking University People's Hospital reported on the results of a study on reducing treatment doses for Chronic Myeloid Leukemia (CML) patients after achieving major molecular remission (abstract S158). During the conference, the "Tumor Watch" publication interviewed Dr. Qian Jiang, who elaborated on the current status of CML treatment, future prospects, and the initial intent and primary outcomes of the dosage reduction study.
Antimicrobial Susceptibility Testing: The Joint Efforts of CLSI and EUCAST丨ECCMID 2023

Antimicrobial Susceptibility Testing: The Joint Efforts of CLSI and EUCAST丨ECCMID 2023

Antimicrobial susceptibility testing (AST) is pivotal in both individualized and empirical treatments. Notably, standards set for interpreting AST results enable clinicians to choose suitable medications and optimal treatment plans, acting as a significant tool in controlling antimicrobial resistance. The most influential bodies in this space are the Clinical and Laboratory Standards Institute (CLSI) of the United States and the European Committee on Antimicrobial Susceptibility Testing (EUCAST). These entities aim to standardize AST procedures and reduce experimental errors.